Kedudukan dalam Saham
#5977
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Perubahan (1 tahun)
400.72%
Perdagangan Nanobiotix S.A. (NANO)
Harga NANO dengan permodalan pasaran b
Modal pasaran bagi Nanobiotix S.A.(NANO)
Modal Pasaran: $2.29B
Sehingga August 2026, Nanobiotix S.A. mempunyai modal pasaran sebanyak $2.29B. Ini menjadikan Nanobiotix S.A. syarikat ke-5977th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Nanobiotix S.A. dari 2012 hingga 2026
NANO berbanding dengan 5 teratas yang paling popular stocks
| Harga NANO |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.460T
|
+238,096.78%
|
|
|
|
|
$4.623T
|
+201,581.80%
|
|
|
|
|
$4.104T
|
+178,933.88%
|
|
|
|
|
$3.713T
|
+161,869.68%
|
|
|
|
|
$2.756T
|
+120,135.32%
|
